Business Standard

Sunday, December 22, 2024 | 02:49 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Aurobindo Pharma slips 8% on USFDA warning for Andhra Pradesh facility

The company said it believes the existing business from this facility will not be impacted

Indians and Chinese supply 80 per cent of active ingredients to the US  and Indians alone are responsible for  40-45 per cent of finished dosages
Premium

SI Reporter Mumbai
Aurobindo Pharma shares slipped 8 per cent to Rs 579 on the BSE in early morning trade on Friday after the company received a warning letter from US health regulator for its Unit XI, API (Active Pharmaceutical Ingredients) manufacturing facility in Srikakulam, Andhra Pradesh.

The stock was trading close to its 52-week low of Rs 566 touched on July 19, 2018 on the BSE in intra-day trade.

The company said the action follows the earlier inspection of the site by the USFDA (United States Food and Drug Administration) agency in February 2019.

“The Company has received a

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in